Covid19-Sources

4443 bookmarks
Custom sorting
Christian Fries auf Twitter: "Vorschlag für ein effektiveres (reaktiveres) Steuerinstrument im #Corona Management. (Request for Comments) 🔵 Maßnahmen sollten kombiniert an die Inzidenz und die Veränderung der Inzidenz gebunden werden. 1/16" / Twitter
Christian Fries auf Twitter: "Vorschlag für ein effektiveres (reaktiveres) Steuerinstrument im #Corona Management. (Request for Comments) 🔵 Maßnahmen sollten kombiniert an die Inzidenz und die Veränderung der Inzidenz gebunden werden. 1/16" / Twitter
Vorschlag für ein effektiveres (reaktiveres) Steuerinstrument im #Corona Management.(Request for Comments)🔵 Maßnahmen sollten kombiniert an die Inzidenz und die Veränderung der Inzidenz gebunden werden.1/16— Christian Fries (@f2135) March 21, 2021
·twitter.com·
Christian Fries auf Twitter: "Vorschlag für ein effektiveres (reaktiveres) Steuerinstrument im #Corona Management. (Request for Comments) 🔵 Maßnahmen sollten kombiniert an die Inzidenz und die Veränderung der Inzidenz gebunden werden. 1/16" / Twitter
Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patients | medRxiv
Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patients | medRxiv
Background While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalization. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence we focus on mild COVID-19 in non-hospitalized...
·medrxiv.org·
Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patients | medRxiv
🔴 Dominik Scharpf auf Twitter: "#COVID19 Sehr gute Nachrichten! Studie zu inhalativem Budesonid ist jetzt im @TheLancet veröffentlicht (bisher nur preprint). In der frühen Krankheitsphase verhindert Budesonid häufig schwere Verläufe, schnellere Genesung. Keine rel. Nebenwirkungen. https://t.co/DGB5NV3eRc" / Twitter
🔴 Dominik Scharpf auf Twitter: "#COVID19 Sehr gute Nachrichten! Studie zu inhalativem Budesonid ist jetzt im @TheLancet veröffentlicht (bisher nur preprint). In der frühen Krankheitsphase verhindert Budesonid häufig schwere Verläufe, schnellere Genesung. Keine rel. Nebenwirkungen. https://t.co/DGB5NV3eRc" / Twitter
#COVID19Sehr gute Nachrichten! Studie zu inhalativem Budesonid ist jetzt im @TheLancet veröffentlicht (bisher nur preprint). In der frühen Krankheitsphase verhindert Budesonid häufig schwere Verläufe, schnellere Genesung. Keine rel. Nebenwirkungen. https://t.co/DGB5NV3eRc— 🔴 Dominik Scharpf (@dscharpfMD) April 11, 2021
·twitter.com·
🔴 Dominik Scharpf auf Twitter: "#COVID19 Sehr gute Nachrichten! Studie zu inhalativem Budesonid ist jetzt im @TheLancet veröffentlicht (bisher nur preprint). In der frühen Krankheitsphase verhindert Budesonid häufig schwere Verläufe, schnellere Genesung. Keine rel. Nebenwirkungen. https://t.co/DGB5NV3eRc" / Twitter
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals | medRxiv
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals | medRxiv
The SARS-CoV-2 pandemic has been raging for over a year, creating global detrimental impact. The BNT162b2 mRNA vaccine has demonstrated high protection levels, yet apprehension exists that several variants of concerns (VOCs) can surmount the immune defenses generated by the vaccines. Neutralization assays have revealed some reduction in neutralization of VOCs B.1.1.7 and B.1.351, but the relevance of these assays in real life remains unclear. Here, we performed a case-control study that examined whether BNT162b2 vaccinees with documented SARS-CoV-2 infection were more likely to become infec...
·medrxiv.org·
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals | medRxiv
Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide, population-based seroepidemiological surveys | medRxiv
Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide, population-based seroepidemiological surveys | medRxiv
Background. Seroprevalence studies have proven an important tool to monitor the progression of the coronavirus disease 2019 (COVID–19) epidemic. We present results of consecutive population-based seroprevalence surveys performed in Denmark in 2020. Methods. Invitation letters including a questionnaire covering symptoms were sent to representatively drawn samples of the population in spring, late summer and autumn/winter of 2020. Blood samples from participants taken at public test-centers were analyzed for total Ig and seroprevalence estimates per population segment calculated and compared ...
·medrxiv.org·
Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide, population-based seroepidemiological surveys | medRxiv
microCOVID Project
microCOVID Project
A calculator for building intuition about COVID risk. We used published research to estimate the risk level of various activities in microCOVIDs. 1 microCOVID is a one-in-a-million chance of getting COVID. We hope you'll use this tool to make safer choices.
·microcovid.org·
microCOVID Project
(1) John Burn-Murdoch auf Twitter: "NEW: just updated our excess deaths figures, including data into April It’s abundantly clear that Latin America is the hardest-hit region in the world, with the five highest excess death rates globally. The UK is 21st out of 48 countries, and the US 24th https://t.co/JxVd2cG7KI https://t.co/DxNPGA2wNt" / Twitter
(1) John Burn-Murdoch auf Twitter: "NEW: just updated our excess deaths figures, including data into April It’s abundantly clear that Latin America is the hardest-hit region in the world, with the five highest excess death rates globally. The UK is 21st out of 48 countries, and the US 24th https://t.co/JxVd2cG7KI https://t.co/DxNPGA2wNt" / Twitter
NEW: just updated our excess deaths figures, including data into AprilIt’s abundantly clear that Latin America is the hardest-hit region in the world, with the five highest excess death rates globally. The UK is 21st out of 48 countries, and the US 24thhttps://t.co/JxVd2cG7KI pic.twitter.com/DxNPGA2wNt— John Burn-Murdoch (@jburnmurdoch) April 6, 2021
·twitter.com·
(1) John Burn-Murdoch auf Twitter: "NEW: just updated our excess deaths figures, including data into April It’s abundantly clear that Latin America is the hardest-hit region in the world, with the five highest excess death rates globally. The UK is 21st out of 48 countries, and the US 24th https://t.co/JxVd2cG7KI https://t.co/DxNPGA2wNt" / Twitter
Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 | Science
Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 | Science
A minority of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit most infections. How does this happen? Sun et al. reconstructed transmission in Hunan, China, up to April 2020. Such detailed data can be used to separate out the relative contribution of transmission control measures aimed at isolating individuals relative to population-level distancing measures. The authors found that most of the secondary transmissions could be traced back to a minority of infected individuals, and well over half of transmission occurred in the presymptomatic phase. F...
·science.sciencemag.org·
Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 | Science
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
In this Perspective, Cobey, Larremore, Grad and Lipsitch argue that dose-sparing regimens of COVID-19 vaccines can reduce disease incidence, prevalence and burden and explain why they think that such strategies would also slow the rate of viral escape from vaccine or naturally induced immunity.
·nature.com·
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
Our study provides evidence for substantial neurological and psychiatric morbidity in the 6 months after COVID-19 infection. Risks were greatest in, but not limited to, patients who had severe COVID-19. This information could help in service planning and identification of research priorities. Complementary study designs, including prospective cohorts, are needed to corroborate and explain these findings.
·thelancet.com·
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
Covid-19: What have we learnt about the new variant in the UK? | The BMJ
Covid-19: What have we learnt about the new variant in the UK? | The BMJ
The new SARS-CoV-2 variant has evoked scenes reminiscent of the early days of covid-19 when much of the world banned travel to and from Wuhan, China. With large parts of south-east England locked down, Elisabeth Mahase looks at what we know so far Yes, according to a review of the current evidence by the UK’s New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). Its 18 December report said that the rate of transmission of the variant, known as B.1.1.7 or VUI 202012/01 (variant under investigation, year 2020, month 12, variant 01), was 71% (95% confidence interval 67% to 75%),...
·bmj.com·
Covid-19: What have we learnt about the new variant in the UK? | The BMJ
Myths of Vaccine Manufacturing | In the Pipeline
Myths of Vaccine Manufacturing | In the Pipeline
In the last few days, the question of why more drug companies haven't been enlisted for vaccine production has come up. It's mostly due to this tweet: The problem is, as far as I can see, this is simply wrong. There are not "dozens of other pharma companies" who "stand ready" to produce these
·blogs.sciencemag.org·
Myths of Vaccine Manufacturing | In the Pipeline
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance | Blood | American Society of Hematology
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance | Blood | American Society of Hematology
Abstract. Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors. The mechanism underlying this phenom
·ashpublications.org·
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance | Blood | American Society of Hematology
Corona-Ansteckung wohl nicht übers Auge
Corona-Ansteckung wohl nicht übers Auge
Eine SARS-CoV-2-Infektion über die Augenoberfläche erscheint unwahrscheinlich, berichten Augenärzte. Dennoch sei ein Augenschutz für medizinisches Personal im Umgang mit COVID-19-Patienten ratsam, heißt es bei einer DOG-Tagung.
·aerztezeitung.de·
Corona-Ansteckung wohl nicht übers Auge